Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity

Drug Discovery Today

Volumn 14, Issue 3-4, 2009, Pages 208-213

  Argilés, Josep M ^a   López Soriano, Francisco J ^a   Busquets, Sílvia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15;

DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; HUMAN; LIPID METABOLISM; MUSCLE ATROPHY; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW;

ANIMALS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-15; MUSCLE, SKELETAL; OBESITY; T-LYMPHOCYTES; WASTING SYNDROME;

EID: 58849158244     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.10.010     Document Type: Review

References (54)

1. Grabstein K.H., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264 (1994) 965-968
2. Burton J.D., et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4935-4939
3. Carson W.E., et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180 (1994) 1395-1403
4. Armitage R.J., et al. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 154 (1995) 483-490
5. Akbar A.N., et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26 (1996) 294-299
6. Girard D., et al. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. Blood 88 (1996) 3176-3184
7. Giri J.G., et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13 (1994) 2822-2830
8. Nielsen A.R., et al. Association between IL-15 and obesity: IL-15 as a potential regulator of fat mass. J. Clin. Endocrinol. Metab. (2008) [Epub ahead of print]
9. Carroll H.P., et al. Crossed signals: the role of interleukin-15 and -18 in autoimmunity. Rheumatology 47 (2008) 1269-1277
10. Quinn L.S., et al. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 136 (1995) 3669-3672
11. Quinn L.S., et al. Interleukin-15 stimulates C2 skeletal myoblast differentiation. Biochem. Biophys. Res. Commun. 239 (1997) 6-10
12. Furmanczyk P.S., and Quinn L.S. Interleukin-15 increases myosin accretion in human skeletal myogenic cultures. Cell Biol. Int. 27 (2003) 845-851
13. Quinn L.S., et al. Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp. Cell Res. 280 (2002) 55-63
14. Fuster, G. (2007) PPAR-delta mediates IL-15 action in myotubes: effects of hyperthermia. Int. J. Biochem. Cell Biol. (submitted for publication)
15. Almendro V., et al. Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. Biochim. Biophys. Acta 1761 (2006) 37-42
16. Riechman S.E., et al. Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J. Appl. Physiol. 97 (2004) 2214-2219
17. Nielsen A.R., et al. Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J. Physiol. 584 Pt 1 (2007) 305-312
18. Busquets S., et al. Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int. J. Mol. Med. 16 (2005) 471-476
19. Busquets S., et al. Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim. Biophys. Acta 1760 (2006) 1613-1617
20. Carbo N., et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br. J. Cancer 83 (2000) 526-531
21. van Royen M., et al. DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia?. Biochem. Biophys. Res. Commun. 270 (2000) 533-537
22. Figueras M., et al. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett. 569 (2004) 201-206
23. Ricquier D., and Bouillaud F. The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. Biochem. J. 345 Pt 2 (2000) 161-179
24. Dormann S., et al. Intercellular induction of apoptosis through modulation of endogenous survival factor concentration: a review. Anticancer Res. 19 (1999) 87-103
25. Carbo N., et al. TNF-alpha is involved in activating DNA fragmentation in skeletal muscle. Br. J. Cancer 86 (2002) 1012-1016
26. Llovera M., et al. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett. 338 (1994) 311-318
27. Busquets S., et al. Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett. 579 (2005) 717-722
28. Alvarez B., et al. TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Lett. 175 (2002) 181-185
29. Harcourt L.J., et al. Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am. J. Pathol. 166 (2005) 1131-1141
30. Pistilli E.E., et al. Interleukin-15 responses to aging and unloading-induced skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 292 (2007) C1298-C1304
31. Carbo N., et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim. Biophys. Acta 1526 (2001) 17-24
32. Ajuwon K.M., and Spurlock M.E. Direct regulation of lipolysis by interleukin-15 in primary pig adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 (2004) R608-611
33. Sanchís D., et al. Oleoyl-estrone induces the loss of body fat in rats. Int. J. Obes. Relat. Metab. Disord. 20 (1996) 588-594
34. Sugimoto T., et al. Chronic effects of AJ-9677 on energy expenditure and energy source utilization in rats. Eur. J. Pharmacol. 519 (2005) 135-145
35. Alvarez B., et al. Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochim. Biophys. Acta 1570 (2002) 33-37
36. Quinn L.S., et al. Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol. Int. 29 (2005) 449-457
37. Almendro, V. (2008) Interleukin-15 inhibits 3T3-L1 adipocyte differentiation by increasing calcineurin expression. Eur. Cytokine Network (submitted for publication)
38. Fuster, G. (2008) Interleukin-15 influences differentiation and apoptosis in adipocytes implications in obesity handling. Cytokine (submitted for publication)
39. Pistilli E.E., et al. Interleukin-15 and interleukin-15R alpha SNPs and associations with muscle, bone, and predictors of the metabolic syndrome. Cytokine 43 (2008) 45-53
40. Di Renzo L., et al. Normal weight obese syndrome: role of single nucleotide polimorphism of IL-15Ralpha and MTHFR 677C → T genes in the relationship between body composition and resting metabolic rate. Eur. Rev. Med. Pharmacol. Sci. 10 (2006) 235-245
41. Almendro V., et al. Interleukin-15 decreases lipid intestinal absorption. Int. J. Mol. Med. 15 (2005) 963-967
42. Quinn, L.S. (2008) Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab. Nov 11 [Epub ahead of print]
43. Lopez-Soriano J., et al. Rat liver lipogenesis is modulated by interleukin-15. Int. J. Mol. Med. 13 (2004) 817-819
44. Suzuki A., et al. Interleukin-15 increases hepatic regenerative activity. J. Hepatol. 45 (2006) 410-418
45. Yonekawa C., et al. IL-15 levels in patients with acute hepatic failure. Res. Commun. Mol. Pathol. Pharmacol. 115-116 (2004) 5-14
46. Yang L., et al. Interleukin-15 inhibits sodium nitroprusside-induced apoptosis of synovial fibroblasts and vascular endothelial cells. Arthritis Rheum. 46 (2002) 3010-3014
47. Angiolillo A.L., et al. Interleukin-15 promotes angiogenesis in vivo. Biochem. Biophys. Res. Commun. 233 (1997) 231-237
48. Oppenheimer-Marks N., et al. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells in vitro and in the SCID mouse-human rheumatoid arthritis model in vivo. J. Clin. Invest. 101 (1998) 1261-1272
49. Ruckert R., et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?. J. Immunol. 165 (2000) 2240-2250
50. Yano S., et al. Interleukin 15 induces the signals of epidermal proliferation through ERK and PI 3-kinase in a human epidermal keratinocyte cell line, HaCaT. Biochem. Biophys. Res. Commun. 301 (2003) 841-847
51. Hanisch U.K., et al. Mouse brain microglia express interleukin-15 and its multimeric receptor complex functionally coupled to Janus kinase activity. J. Biol. Chem. 272 (1997) 28853-28860
52. Kuczynski S., et al. IL-15 is elevated in serum patients with type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 69 3 (2005) 231-236
53. Argiles J.M., et al. Cross-talk between skeletal muscle and adipose tissue: a link with obesity?. Med. Res. Rev. 25 (2005) 49-65
54. Ceddia R.B., et al. The response of skeletal muscle to leptin. Front. Biosci. 6 (2001) D90-D97